In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

ESC Working Group on Cardiovascular Pharmacotherapy

The primary aim of our Working Group is the same as the one ESC promotes; "To reduce the burden of cardiovascular disease in Europe".

Pharmacology is an extremely important aspect of most disciplines within cardiology. All cardiologists use cardiovascular drugs and we believe all cardiologist who are ESC members should join our Working Group to contribute and to learn.

Thus, we are an important contributor to the ESC at most levels. We work with all aspects of cardiovascular pharmacology i.e. from basic pharmacology over clinical trials to clinical pharmacology.

The activity of the Working Group has increased dramatically during the last years. We have now yearly scientific meetings organised by the Working Group focusing on cardiovascular pharmacology.

We have several other educational activities, which we plan to increase during the next years and we have recently launched a new journal within the ESC Journal family, entitled European Heart Journal – Cardiovascular Pharmacotherapy.

Prof. Basil S. Lewis, FESC (Israel)
Chairperson 2016-2018

Aims and Activities


  • To promote and organise research in the field of cardiovascular pharmacology and drug therapy
  • To design and coordinate scientific research in its specialty
  • To be involved in task forces of the European Society of Cardiology related to cardiovascular pharmacology
  • To increase the number of Working Group members


  • To start up and strengthen the new journal of the Working Group, entitled European Heart Journal-Cardiovascular Pharmacotherapy. The journal will come out with 4 issues during 2015 aiming at increasing that number up to 12 issues a year within 5-6 years. An aim with the journal is to become the strongest scientific journal within cardiovascular pharmacology
  • To organise yearly scientific meeting of the Working Group with focus on cardiovascular pharmacology
  • To participate in the production of ESC Clinical Practice Guidelines
  • To publish position papers within the area of the Working Group
  • To contribute to the organisation and preparation of the Annual Congress of the ESC
  • To participate and support other scientific meetings and symposia
  • To organise teaching workshops and other types of education on topics related to cardiovascular pharmacology and drug therapy
  • To hold regular meetings of the nucleus of the Working Group